Short Interest in Venus Concept Inc. (NASDAQ:VERO) Drops By 72.1%

Venus Concept Inc. (NASDAQ:VERO) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 12,900 shares, a drop of 72.1% from the February 29th total of 46,300 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily volume of 536,300 shares, the short-interest ratio is presently 0.0 days.

Venus Concept Price Performance

Venus Concept stock opened at $0.74 on Thursday. The firm has a market capitalization of $4.09 million, a PE ratio of -0.11 and a beta of 0.66. The company’s 50-day moving average is $1.03 and its 200-day moving average is $1.45. Venus Concept has a fifty-two week low of $0.60 and a fifty-two week high of $4.70.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its stake in Venus Concept by 140.2% in the 1st quarter. Bank of New York Mellon Corp now owns 86,578 shares of the company’s stock valued at $124,000 after purchasing an additional 50,530 shares during the last quarter. HighTower Advisors LLC bought a new stake in Venus Concept during the 1st quarter worth approximately $31,000. Vanguard Group Inc. boosted its holdings in Venus Concept by 2.3% in the first quarter. Vanguard Group Inc. now owns 1,121,558 shares of the company’s stock valued at $1,603,000 after acquiring an additional 25,630 shares during the last quarter. Prelude Capital Management LLC raised its stake in Venus Concept by 73.4% during the first quarter. Prelude Capital Management LLC now owns 177,246 shares of the company’s stock worth $253,000 after buying an additional 75,000 shares during the last quarter. Finally, SVB Financial Group acquired a new stake in Venus Concept during the 4th quarter worth about $51,000. 87.41% of the stock is owned by institutional investors.

About Venus Concept

Venus Concept Inc, a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.